Moreover, an inhibitor of ZAK, iZAK2 could suppress pathogenic characteristics of lupus-like inflammation, and our previous work has shown that iZAK2 could also ameliorate autoimmune inflammation in aged mice [20], both of which support the potential therapeutic benefits of iZAK2. Here, MAP3K20 is linked to inflammatory response.